Actively Recruiting

Phase 2
Age: 60Years +
All Genders
NCT07338682

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

Led by German University in Cairo · Updated on 2026-01-21

60

Participants Needed

1

Research Sites

43 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.

CONDITIONS

Official Title

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >60 years
  • Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
Not Eligible

You will not qualify if you...

  • Presence of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, or Multiple Sclerosis
  • History of L-arginine intolerance or allergy
  • History of asthma
  • Recent acute myocardial infarction
  • Stroke within the past 1 year
  • Changes in medications affecting cognitive function (CNS psychotropics, antihistamines, acetylcholinesterase inhibitors) during the study
  • Changes in antihypertensive medications during the study
  • Changes in antidiabetic medications during the study
  • Changes in antihyperlipidemic medications during the study
  • Use of medications for depression, anxiety, or stress that may impact cognition
  • Use of nitrates, phosphodiesterase-5 inhibitors, or potassium-sparing diuretics
  • Refusal to provide written informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Neurology Department, Al-Azhar University Hospitals

Cairo, Egypt

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here